Compare ASTRAZENECA PHARMA with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PFIZER - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PFIZER ASTRAZENECA PHARMA/
PFIZER
 
P/E (TTM) x 73.6 33.4 220.3% View Chart
P/BV x 20.7 5.6 370.0% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   PFIZER
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
PFIZER
Mar-18
ASTRAZENECA PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,2782,365 54.0%   
Low Rs8831,625 54.3%   
Sales per share (Unadj.) Rs228.4430.3 53.1%  
Earnings per share (Unadj.) Rs10.478.7 13.2%  
Cash flow per share (Unadj.) Rs16.393.2 17.4%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs98.8586.5 16.8%  
Shares outstanding (eoy) m25.0045.75 54.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.6 102.0%   
Avg P/E ratio x104.225.3 411.2%  
P/CF ratio (eoy) x66.421.4 310.3%  
Price / Book Value ratio x10.93.4 321.5%  
Dividend payout %025.4 0.0%   
Avg Mkt Cap Rs m27,00891,271 29.6%   
No. of employees `0001.42.6 51.6%   
Total wages/salary Rs m1,5353,143 48.8%   
Avg. sales/employee Rs Th4,210.97,484.8 56.3%   
Avg. wages/employee Rs Th1,132.21,195.0 94.7%   
Avg. net profit/employee Rs Th191.11,369.1 14.0%   
INCOME DATA
Net Sales Rs m5,71019,685 29.0%  
Other income Rs m1231,143 10.7%   
Total revenues Rs m5,83320,828 28.0%   
Gross profit Rs m4635,003 9.3%  
Depreciation Rs m147663 22.2%   
Interest Rs m04 0.0%   
Profit before tax Rs m4385,479 8.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,878 9.5%   
Profit after tax Rs m2593,601 7.2%  
Gross profit margin %8.125.4 31.9%  
Effective tax rate %40.834.3 119.1%   
Net profit margin %4.518.3 24.8%  
BALANCE SHEET DATA
Current assets Rs m3,20924,167 13.3%   
Current liabilities Rs m2,0709,544 21.7%   
Net working cap to sales %20.074.3 26.9%  
Current ratio x1.62.5 61.2%  
Inventory Days Days7255 131.3%  
Debtors Days Days3529 121.7%  
Net fixed assets Rs m7909,514 8.3%   
Share capital Rs m50458 10.9%   
"Free" reserves Rs m2,41926,375 9.2%   
Net worth Rs m2,46926,832 9.2%   
Long term debt Rs m025 0.0%   
Total assets Rs m4,60536,900 12.5%  
Interest coverage xNM1,305.5-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.5 232.4%   
Return on assets %5.69.8 57.6%  
Return on equity %10.513.4 78.2%  
Return on capital %17.720.4 86.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30022 1,337.3%   
Fx outflow Rs m2,0151,489 135.3%   
Net fx Rs m-1,715-1,466 117.0%   
CASH FLOW
From Operations Rs m883,318 2.6%  
From Investments Rs m-94-2,383 3.9%  
From Financial Activity Rs mNA-1,104 0.0%  
Net Cashflow Rs m-6-169 3.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 63.9 117.4%  
Indian inst/Mut Fund % 0.3 7.5 4.0%  
FIIs % 15.7 4.9 320.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 23.7 38.4%  
Shareholders   12,856 85,207 15.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON   STERLING BIOTECH  NATCO PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - TTK HEALTHCARE COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS